Laila Arash

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study

Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz et al. · The Journal of Pediatrics · 2006 · 364 citations

Life Sciences, Biochemistry, Pharmacotherapy +7

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz et al. · Molecular Genetics and Metabolism · 2008 · 216 citations

Life Sciences, Biochemistry, Clinical Biochemistry +8

Clinical course of sly syndrome (mucopolysaccharidosis type VII)

Adriana M. Montaño, Robert D. Steiner, Brett H. Graham et al. · Journal of Medical Genetics · 2016 · 165 citations · Full text

Life Sciences, Genetics, Pediatrics +13

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long‐term pulmonary function in patients treated with recombinant human <i>N</i>‐acetylgalactosamine 4‐sulfatase

Paul Harmatz, Zi‐Fan Yu, Roberto Giugliani et al. · Journal of Inherited Metabolic Disease · 2010 · 92 citations · Full text

Health Professions, Pharmacotherapy, Clinical Biochemistry +10

Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase

Celeste Decker, Zi‐Fan Yu, Roberto Giugliani et al. · Journal of Pediatric Rehabilitation Medicine · 2010 · 66 citations · Full text

Life Sciences, Pediatrics, Pharmacotherapy +14